Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
What Is The Dividend Outlook For Outfront Media Out Stock Price At 29.03 Down 0.35 20260328 Buckle BKE Q1 2026 Earnings Beat Revenue NA EPS 159 Burlington BURL Drops 114 Key Support at 27575 20260518 Rupee Weakens 18 Paise to 9638 vs US Dollar as Crude Oil Concerns Mount Why Ironwood Pharmaceuticals IRWD Just Dropped 223 What to Watch 20260518 Neuronetics STIM Q1 2026 Beat Revenue NA EPS Exceeds by Significant BlackRock Utility Infrastructure Power Opportunities Trust BUI Gains on Sector Strength The Beauty SKIN Jumps 226 on Strong Momentum 20260520 SPS Commerce SPSC Holds Steady Near Support Amid Modest Decline Oil Prices Decline as USIran Talks Show Progress but Key Disagreements Persist Korea Post Targets AI Data Centers and Real Estate Investments to Offset Mail Business Losses Microsofts GitHub Faces Headwinds in AI Coding Race Amid Outages and Rising Competition Global Markets Navigate Volatility Amid Geopolitical Tensions Inflation and AI Disruption Retailers Navigate KShaped Economy with Dual Strategy of Price Cuts and Premiumization Summer Utility Bills Rise as Cooling Costs Heat Up PCOR Q1 2026 Earnings EPS Falls Short of Estimates Stock Edges Higher FN Q1 2026 Earnings EPS Beats Estimates Surprise of 147 Centene Q1 2026 Earnings EPS Surges 56 Above Estimates as Managed Care Segment Shows Strength LITE Q1 2026 Earnings EPS Beats Estimates Revenue Impact Unclear Stock Down 182 EchoStar SATS Q1 2026 Earnings Significant EPS Beat Driven by Cost Control and Subscriber Trends American Shared Hospital Services AMS Q1 2026 Earnings Significant EPS Miss Amid Operational Challenges QT Imaging Holdings QTI Modest Gains Near Support as Stock Holds Steady Coty Inc COTY Stabilizes Near Key Support Amid Flat Trading Session GRAIL Inc GRAL Advances Over 35 as Momentum Tests Key Resistance Zone AllianceBernstein AB Holds Steady Near 37 Amidst Modest Pullback Acrivon Therapeutics ACRV Narrows Lower as Biotech Sentiment Remains Cautious